{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T23:10:10Z","timestamp":1744240210401,"version":"3.40.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14014-1","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T22:47:37Z","timestamp":1744238857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of monotherapy and combination therapy for older patients with advanced biliary tract cancer: a retrospective study"],"prefix":"10.1186","volume":"25","author":[{"given":"Ritsuko","family":"Oishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taito","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Tezuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"14014_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397:428\u201344.","journal-title":"Lancet"},{"key":"14014_CR2","doi-asserted-by":"publisher","first-page":"100226","DOI":"10.1016\/j.jhepr.2021.100226","volume":"3","author":"A Moeini","year":"2021","unstructured":"Moeini A, Haber PK, Sia D. Cell of origin in biliary tract cancers and clinical implications. JHEP Rep. 2021;3:100226.","journal-title":"JHEP Rep"},{"key":"14014_CR3","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1200\/EDBK_160831","volume":"35","author":"JA Bridgewater","year":"2016","unstructured":"Bridgewater JA, Goodman KA, Kalyan A, Mulcahy MF. Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling. Am Soc Clin Oncol Educ Book. 2016;35:e194\u2013203.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"14014_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.21037\/cco.2016.10.09","volume":"5","author":"L Marcano-Bonilla","year":"2016","unstructured":"Marcano-Bonilla L, Mohamed EA, Mounajjed T, Roberts LR. Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations. Chin Clin Oncol. 2016;5:61.","journal-title":"Chin Clin Oncol"},{"key":"14014_CR5","unstructured":"Cancer Information Service, National Cancer Center, Japan. Cancer Registry and Statistics, Ministry of Health, Labour and Welfare, National Cancer Registry 2018. https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/en.html. Accessed 30 July 2024."},{"key":"14014_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1470-7330-14-14","volume":"14","author":"TP Hennedige","year":"2014","unstructured":"Hennedige TP, Neo WT, Venkatesh SK. Imaging of malignancies of the biliary tract- an update. Cancer Imaging. 2014;14:14.","journal-title":"Cancer Imaging"},{"key":"14014_CR7","doi-asserted-by":"publisher","first-page":"101936","DOI":"10.1016\/j.ctrv.2019.101936","volume":"84","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Edeline J, McNamara MG, Hubner RA, Nagino M, Bridgewater J, et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat Rev. 2020;84:101936.","journal-title":"Cancer Treat Rev"},{"key":"14014_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jhbp.314","volume":"23","author":"S Ishihara","year":"2016","unstructured":"Ishihara S, Horiguchi A, Miyakawa S, Endo I, Miyazaki M, Takada T. Biliary tract cancer registry in Japan from 2008 to 2013. J Hepatobiliary Pancreat Sci. 2016;23:149\u201357.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"14014_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/jhbp.870","volume":"28","author":"M Nagino","year":"2021","unstructured":"Nagino M, Hirano S, Yoshitomi H, Aoki T, Uesaka K, Unno M, et al. Clinical practice guidelines for the management of biliary tract cancers 2019: the 3rd english edition. J Hepatobiliary Pancreat Sci. 2021;28:26\u201354.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"14014_CR10","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/jhbp.1418","volume":"31","author":"M Ueno","year":"2024","unstructured":"Ueno M, Shirakawa S, Tokumaru J, Ogi M, Nishida K, Hirai T, et al. Real-world evidence of systemic treatment practices for biliary tract cancer in Japan: results of a database study. J Hepatobiliary Pancreat Sci. 2024;31:468\u201380.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"14014_CR11","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"14014_CR12","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30:1950\u20138.","journal-title":"Ann Oncol"},{"key":"14014_CR13","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","volume":"341","author":"LF Hutchins","year":"1999","unstructured":"Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061\u20137.","journal-title":"N Engl J Med"},{"key":"14014_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.critrevonc.2018.08.008","volume":"131","author":"J Feliu","year":"2018","unstructured":"Feliu J, Heredia-Soto V, Giron\u00e9s R, Jim\u00e9nez-Munarriz B, Salda\u00f1a J, Guill\u00e9n-Ponce C, et al. Can we avoid the toxicity of chemotherapy in elderly cancer patients? Crit Rev Oncol Hematol. 2018;131:16\u201323.","journal-title":"Crit Rev Oncol Hematol"},{"key":"14014_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/aac2.12054","volume":"3","author":"X Weng","year":"2022","unstructured":"Weng X, Song X, Shao R, Liu F, Liu Y. Aging and biliary tract cancers: epidemiology, molecular biology, and clinical practice. Aging Cancer. 2022;3:95\u2013104.","journal-title":"Aging Cancer"},{"key":"14014_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"14014_CR17","unstructured":"National Cancer Institute. Division of Cancer Treatment & Diagnosis 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed 30 July 2024."},{"key":"14014_CR18","doi-asserted-by":"publisher","first-page":"44995","DOI":"10.18632\/oncotarget.5707","volume":"6","author":"A Horgan","year":"2015","unstructured":"Horgan A, Knox J, Aneja P, Le L, McKeever E, McNamara M. Patterns of care and treatment outcomes in older patients with biliary tract cancer. Oncotarget. 2015;6:44995\u20135004.","journal-title":"Oncotarget"},{"key":"14014_CR19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1200\/jco.2016.34.4_suppl.382","volume":"34 4suppl","author":"MG McNamara","year":"2016","unstructured":"McNamara MG, Bridgewater JA, Lopes A, Wasan H, Malka D, Jensen HR, et al. Systemic therapy in elderly patients with advanced biliary tract cancer: Sub-analysis of ABC-02 and 10 other prospective studies. J Clin Oncol. 2016;34 4suppl:382\u2013382.","journal-title":"J Clin Oncol"},{"key":"14014_CR20","doi-asserted-by":"crossref","unstructured":"McNamara MG, de Liguori Carino N, Kapacee ZA, Lamarca A, Valle JW. Outcomes in older patients with biliary tract cancer. Eur J Surg Oncol. 2021;47 3 Pt A:569\u2013\u200975.","DOI":"10.1016\/j.ejso.2020.03.202"},{"key":"14014_CR21","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/s41598-021-04550-8","volume":"12","author":"I Yamada","year":"2022","unstructured":"Yamada I, Morizane C, Okusaka T, Mizusawa J, Kataoka T, Ueno M, et al. The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113. Sci Rep. 2022;12:987.","journal-title":"Sci Rep"},{"key":"14014_CR22","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.lungcan.2018.02.011","volume":"119","author":"H Borghaei","year":"2018","unstructured":"Borghaei H, Yim YM, Guerin A, Pivneva I, Shi S, Gandhi M, et al. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy. Lung Cancer. 2018;119:112\u20139.","journal-title":"Lung Cancer"},{"key":"14014_CR23","doi-asserted-by":"publisher","first-page":"5158","DOI":"10.3748\/wjg.v21.i17.5158","volume":"21","author":"JH Kim","year":"2015","unstructured":"Kim JH. Chemotherapy for colorectal cancer in the elderly. World J Gastroenterol. 2015;21:5158\u201366.","journal-title":"World J Gastroenterol"},{"key":"14014_CR24","doi-asserted-by":"publisher","first-page":"e000020","DOI":"10.1136\/esmoopen-2015-000020","volume":"1","author":"C Marosi","year":"2016","unstructured":"Marosi C, K\u00f6ller M. Challenge of cancer in the elderly. ESMO Open. 2016;1:e000020.","journal-title":"ESMO Open"},{"key":"14014_CR25","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3390\/cancers16101835","volume":"16","author":"TK Sahin","year":"2024","unstructured":"Sahin TK, Rizzo A, Aksoy S, Guven DC. Prognostic significance of the Royal marsden hospital (RMH) score in patients with cancer: A systematic review and meta-analysis. Cancers (Basel). 2024;16:1835.","journal-title":"Cancers (Basel)"},{"key":"14014_CR26","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1200\/JOP.18.00180","volume":"14","author":"SG Mohile","year":"2018","unstructured":"Mohile SG, Dale W, Somerfield MR, Hurria A. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology summary. J Oncol Pract. 2018;14:442\u20136.","journal-title":"J Oncol Pract"},{"key":"14014_CR27","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","volume":"32","author":"H Wildiers","year":"2014","unstructured":"Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen MLG, Extermann M, et al. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32:2595\u2013603.","journal-title":"J Clin Oncol"},{"key":"14014_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JCO.2013.51.1345","volume":"32","author":"C Kenis","year":"2014","unstructured":"Kenis C, Decoster L, Van Puyvelde K, De Gr\u00e8ve J, Conings G, Milisen K, et al. Performance of two geriatric screening tools in older patients with cancer. J Clin Oncol. 2014;32:19\u201326.","journal-title":"J Clin Oncol"},{"key":"14014_CR29","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1:EVIDoa2200015.","journal-title":"NEJM Evid"},{"key":"14014_CR30","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853\u201365.","journal-title":"Lancet"},{"key":"14014_CR31","doi-asserted-by":"publisher","first-page":"107327482094804","DOI":"10.1177\/1073274820948047","volume":"27","author":"AD Ricci","year":"2020","unstructured":"Ricci AD, Rizzo A, Brandi G. Immunotherapy in biliary tract cancer: worthy of a second look. Cancer Control. 2020;27:1073274820948047.","journal-title":"Cancer Control"},{"issue":"3","key":"14014_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/CJI.0000000000000312","volume":"43","author":"C Ciccarese","year":"2020","unstructured":"Ciccarese C, Iacovelli R, Bria E, Palazzo A, Maiorano BA, Mosillo C, et al. The anticancer efficacy of immune checkpoint inhibitors according to patients\u2019 age: a systematic review and meta-analysis. J Immunother. 2020;43(3):95\u2013103.","journal-title":"J Immunother"},{"key":"14014_CR33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ctrv.2016.02.006","volume":"45","author":"TF Nishijima","year":"2016","unstructured":"Nishijima TF, Muss HB, Shachar SS, Moschos SJ. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat Rev. 2016;45:30\u20137.","journal-title":"Cancer Treat Rev"},{"key":"14014_CR34","doi-asserted-by":"publisher","first-page":"e001042","DOI":"10.1136\/esmoopen-2020-001042","volume":"5","author":"AD Ricci","year":"2020","unstructured":"Ricci AD, Rizzo A, Brandi G. The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora\u2019s box? ESMO Open. 2020;5:e001042.","journal-title":"ESMO Open"},{"key":"14014_CR35","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/17425255.2021.2029405","volume":"17","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Santoni M, Mollica V, Logullo F, Rosellini M, Marchetti A, et al. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opin Drug Metab Toxicol. 2021;17:1455\u20136632.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"14014_CR36","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00520-023-08083-w","volume":"31","author":"DC Guven","year":"2023","unstructured":"Guven DC, Erul E, Kaygusuz Y, Akagunduz B, Kilickap S, De Luca R, et al. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Support Care Cancer. 2023;31:624.","journal-title":"Support Care Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14014-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14014-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14014-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T22:47:42Z","timestamp":1744238862000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14014-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14014"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14014-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board of the Kanagawa Cancer Center (ID: 2021-41) and was conducted according to the Declaration of Helsinki. The participants were given the opportunity to opt out of having their information published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"\u30fbS. Kobayashi received honoraria for speakers\u2019 bureaus from AstraZeneca plc, MSD K.K., and Taiho Pharmaceutical Co., Ltd.\u30fbM. Ueno received grants from Taiho Pharmaceutical Co., Ltd., AstraZeneca K.K., MSD K.K., Nihon Servier Co., Ltd., Ono Pharmaceutical Co., Ltd., Incyte Biosciences Japan GK, Chugai Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, Eisai Co., Ltd., Novartis Pharma K.K., Astellas Pharma Inc., J-pharma Co., Ltd., DFP (Delta-Fly Pharma), Inc., Novocure GmbH, and Chiome Bioscience Inc., and honoraria for speakers\u2019 bureaus from Taiho Pharmaceutical Co., Ltd., AstraZeneca K.K., Yakult Honsha Co., Ltd., MSD K.K., Nihon Servier Co., Ltd., Ono Pharmaceutical Co., Ltd., Incyte Biosciences Japan GK, Chugai Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, J-pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Novartis Pharma K.K.\u30fbThe other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"653"}}